DrugCite
Search

PIASCLEDINE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Piascledine Adverse Events Reported to the FDA Over Time

How are Piascledine adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Piascledine, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Piascledine is flagged as the suspect drug causing the adverse event.

Most Common Piascledine Adverse Events Reported to the FDA

What are the most common Piascledine adverse events reported to the FDA?

Dehydration
8 (3.21%)
Hyperkalaemia
8 (3.21%)
Thrombocytopenia
8 (3.21%)
Bleeding Anovulatory
7 (2.81%)
Ecchymosis
7 (2.81%)
Jaundice
7 (2.81%)
Purpura
7 (2.81%)
Renal Failure
7 (2.81%)
Diarrhoea
6 (2.41%)
Fall
6 (2.41%)
General Physical Health Deteriorati...
6 (2.41%)
Show More Show More
Metabolic Acidosis
6 (2.41%)
Pain In Extremity
6 (2.41%)
Cholestasis
5 (2.01%)
Cytolytic Hepatitis
5 (2.01%)
Insomnia
5 (2.01%)
Oedema
5 (2.01%)
Dyspnoea
4 (1.61%)
Eructation
4 (1.61%)
Hearing Impaired
4 (1.61%)
Hepatitis
4 (1.61%)
Hypotonia
4 (1.61%)
Malaise
4 (1.61%)
Wound
4 (1.61%)
Abdominal Pain
3 (1.2%)
Cerebrovascular Accident
3 (1.2%)
Liver Function Test Abnormal
3 (1.2%)
Visual Acuity Reduced
3 (1.2%)
Visual Impairment
3 (1.2%)
Blood Amylase Increased
2 (.8%)
Bone Marrow Failure
2 (.8%)
Chest Discomfort
2 (.8%)
Erythema
2 (.8%)
Gait Disturbance
2 (.8%)
Hepatic Fibrosis
2 (.8%)
Hepatic Necrosis
2 (.8%)
Hepatic Steatosis
2 (.8%)
Lipase Increased
2 (.8%)
Mixed Liver Injury
2 (.8%)
Oedema Peripheral
2 (.8%)
Pancreatic Cyst
2 (.8%)
Pancreatic Neoplasm
2 (.8%)
Renal Failure Acute
2 (.8%)
Respiratory Disorder
2 (.8%)
Retinal Artery Thrombosis
2 (.8%)
Rhabdomyolysis
2 (.8%)
Sense Of Oppression
2 (.8%)
Vomiting
2 (.8%)
Weight Decreased
2 (.8%)
Weight Increased
2 (.8%)
Abdominal Pain Upper
1 (.4%)
Alanine Aminotransferase Increased
1 (.4%)
Anaemia
1 (.4%)
Aspartate Aminotransferase Increase...
1 (.4%)
Bicytopenia
1 (.4%)
Blister
1 (.4%)
Blood Alkaline Phosphatase Increase...
1 (.4%)
Blood Creatinine Increased
1 (.4%)
Blood Sodium Decreased
1 (.4%)
Blood Urea Increased
1 (.4%)
Cataract
1 (.4%)
Chills
1 (.4%)
Chronic Obstructive Pulmonary Disea...
1 (.4%)
Condition Aggravated
1 (.4%)
Convulsion
1 (.4%)
Culture Urine Positive
1 (.4%)
Depressed Level Of Consciousness
1 (.4%)
Dialysis
1 (.4%)
Drug Ineffective
1 (.4%)
Dysphagia
1 (.4%)
Eosinophilia
1 (.4%)
Escherichia Infection
1 (.4%)
Febrile Neutropenia
1 (.4%)
Gamma-glutamyltransferase Increased
1 (.4%)
Haemodialysis
1 (.4%)
Haptoglobin Decreased
1 (.4%)
Hepatitis E
1 (.4%)
Hyperaesthesia
1 (.4%)
Hypoglycaemia
1 (.4%)
Hyponatraemia
1 (.4%)
Induration
1 (.4%)
International Normalised Ratio Incr...
1 (.4%)
Lactic Acidosis
1 (.4%)
Leukocyturia
1 (.4%)
Localised Oedema
1 (.4%)
Lung Disorder
1 (.4%)
Maculopathy
1 (.4%)
Mitral Valve Calcification
1 (.4%)
Mitral Valve Disease
1 (.4%)
Mitral Valve Stenosis
1 (.4%)
Multi-organ Failure
1 (.4%)
Nausea
1 (.4%)
Pulmonary Hypertension
1 (.4%)
Pulmonary Oedema
1 (.4%)
Pyrexia
1 (.4%)
Rash Pustular
1 (.4%)
Retinal Artery Occlusion
1 (.4%)
Sensation Of Heaviness
1 (.4%)
Sepsis
1 (.4%)
Septic Shock
1 (.4%)
Skin Fragility
1 (.4%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Piascledine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Piascledine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Piascledine

What are the most common Piascledine adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Piascledine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Piascledine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Piascledine According to Those Reporting Adverse Events

Why are people taking Piascledine, according to those reporting adverse events to the FDA?

Osteoarthritis
35
Drug Use For Unknown Indication
28
Product Used For Unknown Indication
28
Bone Disorder
2
Arteriosclerosis
2
Gingivitis
2
Show More Show More
Musculoskeletal Chest Pain
2
Bone Pain
2
Arthritis
1
Osteoporosis
1
Musculoskeletal Pain
1
Hypertension
1
Anxiety
1

Piascledine Case Reports

What Piascledine safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Piascledine. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Piascledine.